Additional translocation (8;21)(q22;q22) in a patient with philadelphia- positive chronic myelogenous leukaemia in the blastic phase

Kensuke Kojima, Masaki Yasukawa, Fumihiko Ishimaru, Hiromichi Dansako, Yoshinobu Matsuo, Yukio Kimura, Yuichiro Nawa, Masamichi Hara, Mine Harada

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We report a case of Philadelphia-positive chronic myelogenous leukaemia in blastic phase with the additional translocation (8;21)(q22;q22), which is frequent in acute myeloid leukaemia but not in chronic myelogenous leukaemia. The t(8;21) was not detected in the chronic phase, and was the only additional chromosomal anomaly in the blastic clone. Reverse transcription- polymerase chain reaction revealed the AML1/ETO fusion transcript in the cells of blastic phase but not in those of chronic phase. Regarding t(9;22), the breakpoint on chromosome 22 occurred in the μ-BCR region of the BCR gene, resulting in hybrid BCR/ABL mRNA with an e19a2 junction. Our findings provided molecular evidence that t(8;21) can occur as an additional genetic change in Philadelphia-positive chronic myelogenous leukaemia.

Original languageEnglish
Pages (from-to)720-722
Number of pages3
JournalBritish Journal of Haematology
Volume106
Issue number3
DOIs
Publication statusPublished - Sep 24 1999

Keywords

  • Chronic myelogenous leukaemia
  • E19a2 type BCR/ABL rearrangement
  • Translocation (8;21)
  • Translocation (9;22)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Additional translocation (8;21)(q22;q22) in a patient with philadelphia- positive chronic myelogenous leukaemia in the blastic phase'. Together they form a unique fingerprint.

  • Cite this